Processing Magazine
  • Subscribe
  • Magazine
  • Events
  • News & Notes
  • Videos
  • Podcasts
  • Webinars
  • White Papers
  • 3D Models
  • Breakthrough Products Awards
  • Maintenance & Safety
  • Material Handling
  • Mixing & Blending
  • Powder & Bulk Processing
  • Process Control & Automation
  • Pumps, Motors & Drives
  • Valves & Actuators
  • Topics
    Maintenance & SafetyMaterial HandlingMixing, Blending & Size ReductionProcess Control & AutomationPumps, Motors & DrivesValves & ActuatorsPowder & Bulk Solids
    Resources
    MagazineEventsNews & NotesVideosPodcastsWebinarsWhite PapersBreakthrough Products Awards
    User Tools
    SubscribeAdvertiseAbout UsContact UsPrivacy PolicyTerms & Conditions
    http://www.facebook.com/ProcessingMagazine
    https://www.linkedin.com/showcase/27062974
    https://twitter.com/ProcessingMag
    1. Maintenance & Safety
    2. Standards & Regulations

    FDA warns of counterfeit botox

    May 7, 2013

    The U.S. FDA has warned in recent days that fraudulent versions of Allergan’s drug Botox are being distributed here in the U.S. The agency called for healthcare practitioners and the general public to exercise caution when dealing with the drug.

    Staff
    botox
    botox
    Ts 100172859 720
    The counterfeit product is sold in a package identical to that made for the U.S. market, making it appear to be the same drug.

    The U.S. Food and Drug Administration (FDA) has warned in recent days that fraudulent versions of Allergan's drug Botox are being distributed on the U.S. market. In an official statement, the FDA said that the fraudulent drug is not approved by the agency and called on healthcare practitioners and the general public to exercise caution when dealing with the drug.

    The counterfeit product is sold in a package identical to that made for the U.S. market, making it appear to be the same drug. However, the vial inside is labeled as a foreign version of Botox, which is not allowed for sale in the United States. The product is being distributed by unlicensed firms and, because of that, the FDA cannot be certain that it is compliant with U.S. standards regarding manufacturing, storage and handling of medical products. The agency therefore recommends that the products are not used, as they are considered unsafe.

    RELATED: FDA requests higher budget for 2014

    The counterfeit versions of Botox are sold by a company that goes by the names "Online Botox Pharmacy," "Onlinebotox.com," and "Onlinebotox." By the time the public alert was issued, the products did not appear to be available online. However, the FDA was presented with evidence that the fake Botox was sold through "blast faxes", usually selling the product at lower prices than the officially approved version. Online Botox Pharmacy uses a U.S. return address when sending packages to medical practices, despite the fact that the products are from foreign sources — a practice which is common for fraudulent product sales, the FDA commented.

    According to licensed manufacturer Allergan, Botox is a purified version of the same toxin that causes botulism and can cause potentially deadly swallowing and breathing difficulties if used wrongly. Last year the product generated sales of $1.77 billion, with about half of this coming from cosmetic use, Reuters reported.

    The FDA warned that medical products manufactured abroad and not having any state or federal approval may be "misbranded, adulterated, counterfeit, contaminated, improperly stored and transported, ineffective, and/or unsafe." It also noted that medical practices that buy and use illegal or unapproved medical products from foreign sources may be compromising patients' health and safety, as they may not be receiving adequate treatment.

    The Botox for injection which the FDA has approved for the U.S. market is manufactured by Allergan and displays the active ingredient as "OnabotulinumtoxinA" on both the outer carton and vial. At present, there is no indication that Allergan's FDA-approved version is at risk, so it can still be considered safe and effective for its intended and approved uses, the FDA statement explained. Medical practices can identify the counterfeit version by two main features: the outer carton shows the active ingredient as "Botulinum Toxin Type A" and the lot number and expiration dates on the outer carton and the vial inside do not match. The public is asked to report suspect Botox products obtained from Online Botox Pharmacy or other questionable sources to the FDA immediately.The U.S. Food and Drug Administration (FDA) has warned in recent days that fraudulent versions of Allergan's drug Botox are being distributed on the U.S. market. In an official statement, the FDA said that the fraudulent drug is not approved by the agency and called on healthcare practitioners and the general public to exercise caution when dealing with the drug.

    The counterfeit product is sold in a package identical to that made for the U.S. market, making it appear to be the same drug. However, the vial inside is labeled as a foreign version of Botox, which is not allowed for sale in the United States. The product is being distributed by unlicensed firms and, because of that, the FDA cannot be certain that it is compliant with U.S. standards regarding manufacturing, storage and handling of medical products. The agency therefore recommends that the products are not used, as they are considered unsafe.

    The counterfeit versions of Botox are sold by a company that goes by the names "Online Botox Pharmacy," "Onlinebotox.com," and "Onlinebotox." By the time the public alert was issued, the products did not appear to be available online. However, the FDA was presented with evidence that the fake Botox was sold through "blast faxes", usually selling the product at lower prices than the officially approved version. Online Botox Pharmacy uses a U.S. return address when sending packages to medical practices, despite the fact that the products are from foreign sources — a practice which is common for fraudulent product sales, the FDA commented.

    According to licensed manufacturer Allergan, Botox is a purified version of the same toxin that causes botulism and can cause potentially deadly swallowing and breathing difficulties if used wrongly. Last year the product generated sales of $1.77 billion, with about half of this coming from cosmetic use, Reuters reported.

    The FDA warned that medical products manufactured abroad and not having any state or federal approval may be "misbranded, adulterated, counterfeit, contaminated, improperly stored and transported, ineffective, and/or unsafe." It also noted that medical practices that buy and use illegal or unapproved medical products from foreign sources may be compromising patients' health and safety, as they may not be receiving adequate treatment.

    The Botox for injection which the FDA has approved for the U.S. market is manufactured by Allergan and displays the active ingredient as "OnabotulinumtoxinA" on both the outer carton and vial. At present, there is no indication that Allergan's FDA-approved version is at risk, so it can still be considered safe and effective for its intended and approved uses, the FDA statement explained. Medical practices can identify the counterfeit version by two main features: the outer carton shows the active ingredient as "Botulinum Toxin Type A" and the lot number and expiration dates on the outer carton and the vial inside do not match. The public is asked to report suspect Botox products obtained from Online Botox Pharmacy or other questionable sources to the FDA immediately.

    Continue Reading

    MG America and Romaco North America announce strategic alliance in North American manufacturing equipment marketplace

    HRS Heat Exchangers gains 3-A approval for key food models

    Sponsored Recommendations

    Cosmo Oil and Yokogawa explore possibilities for refinery digitalization

    Plans include having quadruped robots perform plant inspections and maintenance.

    Processing Pros Ep. 3: Jack Hilbert talks pneumatic conveying

    Senior editor Nate Todd chats with Jack Hilbert about pneumatic conveying phases, common conveying challenges and two things all conveyor end users should know.

    Product focus: Powder and bulk processing

    Screen feeder STEDI-FLO screen feeder by Dynamic Air is a screen and feeder combination using either a single-, double- or triple-deck screen and a brute-force drive with two ...

    Understanding ratholing and bridging phenomena in bulk powder feeding

    Feeder design is critical to maintaining consistent and reliable material flow from storage vessels into processing equipment.

    Latest in Standards & Regulations

    ID 227746257 © Rafael Henrique | Dreamstime.com
    Dreamstime Xxl 227746257
    Standards & Regulations

    Heads up: NFPA 660 Standard for Combustible Dusts is coming

    Jack Osborn
    Aug. 22, 2023
    Photo 101382116 © Péter Gudella | Dreamstime.com
    Dreamstime M 101382116
    Standards & Regulations

    Why product carbon footprint matters — and 3 steps to better measure and manage it

    Marko Lange
    July 28, 2022

    Most Read

    Food safety and quality management with maintenance software and sensors

    NETZSCH building new multiple screw pump factory

    Techceuticals announces relaunch with an expanded focus on the pharmaceutical industry

    Sponsored Recommendations

    Cosmo Oil and Yokogawa explore possibilities for refinery digitalization

    Processing Pros Ep. 3: Jack Hilbert talks pneumatic conveying

    Product focus: Powder and bulk processing

    Processing Magazine
    http://www.facebook.com/ProcessingMagazine
    https://www.linkedin.com/showcase/27062974
    https://twitter.com/ProcessingMag
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo